Q
Qinghui Liannuo
Cell therapy platform for reliable, economical treatments
About Qinghui Liannuo
Beijing Qinghui Liannuo Biotechnology Co., Ltd., also known as Unicet Biotech, is a developer of cell therapy systems founded in 2018. The company focuses on translating research into clinical applications. Its product pipeline is concentrated on γδ (gamma delta) T cell therapy, targeted drugs, and new vaccine adjuvants, aiming to provide patients with dependable and affordable treatment options.
The company's strategic focus includes developing treatments for conditions like malignant gliomas. Unicet Biotech has successfully raised capital to fund its operations and research endeavors. In a notable funding round on November 22, 2021, the company secured $15.6 million in an early-stage venture capital deal. To date, the company has raised a total of $17.1 million. Its investor base includes firms such as Highlight Capital, Lapam Capital, Zhongguancun Co-Innovation Fund, and the Beijing Municipal Commission of Science and Technology.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2026 | $28M | $110M | Shenzhen Capital Group · Zhongwei Feitu · Longpan Investment · Beijing Medical and Health Industry Investment Fund | ↗ |
| SERIES A✓Equity / VC | Jul 2025 | $0 | — | Feitu Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Qinghui Liannuo is 160 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Neovira TherapeuticsOncolytic virus therapies for hard-to-treat cancers |
Bengaluru, India | Operational | 1 | $285K | $1.1M |
| Huangpu, China | Operational | ||||
T-CureT-cell receptor therapies for solid tumor cancers |
Busan, South Korea | Operational | |||
| China | Operational | ||||
Ouro MedicinesBiotechnology firm advancing immune reset therapeutics for chronic immune-mediated diseases with a robust clinical pipeline |
South San Francisco, United States | Acquired | |||
TicarosNext-generation immunotherapies for intractable cancers |
Pyeongtaek, South Korea | Operational | |||
NkiltDeveloping targeted cell therapies for cancer |
Houston, United States | Operational | |||
GilboaGilboa Therapeutics is a immunotherapy firm seeking to transform cancer care with SolidT cell therapy |
Israel | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qinghui Liannuo in the Dongcheng District ecosystem
The Qinghui Liannuo office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Highlight Capital
Series A6 investors entered at this stage
- FCFeitu Venture Capital
Shenzhen Capital Group- ZFZhongwei Feitu
- LILongpan Investment
- BFBeijing Medical and Health Industry Investment Fund
- ZCZhongguancun Kaiyuan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qinghui Liannuo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qinghui Liannuo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






